Bobbi Hullum, APRN
Adult Health · Cortland, OHNPI 1861148454
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,836 of the $9,730 with a category attached, or 80.5%. 32 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 30.2% of the total. Among adult health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- Bayer$1K
- AstraZeneca$791
- OPKO Pharmaceuticals, LLC$564
- Aurinia Pharma U.S., Inc.$506
- Vifor Pharma, Inc.$502
- plus $3K from 26 others
What the payments were for
- Consulting fees$1,86119%
- Food & beverage$7,83681%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 31 | $2,943 |
| Bayer | 46 | $1,001 |
| AstraZeneca(2 entities) | 32 | $791 |
| OPKO Pharmaceuticals, LLC | 30 | $564 |
| Aurinia Pharma U.S., Inc. | 19 | $506 |
| Vifor Pharma, Inc. | 21 | $502 |
| Otsuka America Pharmaceutical, Inc. | 18 | $393 |
| Novo Nordisk | 19 | $373 |
| Ardelyx, Inc. | 11 | $372 |
| Amgen | 19 | $367 |
| Novartis | 17 | $344 |
| Daiichi Sankyo Inc. | 13 | $284 |
| Travere Therapeutics, Inc. | 16 | $243 |
| Renalytix AI, Inc. | 7 | $136 |
| Boehringer Ingelheim | 3 | $128 |
| GSK | 7 | $127 |
| Fresenius USA Marketing, Inc. | 4 | $90 |
| ANI Pharmaceuticals, Inc. | 3 | $68 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $58 |
| Akebia Therapeutics Inc | 2 | $52 |
| Lilly USA, LLC | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Nxstage Medical, Inc. | 2 | $41 |
| Biomerieux Inc | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$2,203
- XPHOZAH 30 MG$126
- Kerendia$106
- LUPKYNIS$105
How this compares
$9,730 in reported general payments places this provider in the 95th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LupkynisVoclosporin | 11 | $107,024 |
| FarxigaDapagliflozin Propanediol | 54 | $34,237 |
| RayaldeeCalcifediol | 21 | $29,646 |
| TrulicityDulaglutide | 24 | $24,154 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $21,578 |
| OzempicSemaglutide | 23 | $20,096 |
| JardianceEmpagliflozin | 19 | $10,287 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $10,283 |
| EntrestoSacubitril/Valsartan | 13 | $9,125 |
| JanuviaSitagliptin Phosphate | 15 | $8,275 |
| Clonidine | 31 | $2,922 |
| Bumetanide | 102 | $2,021 |
| Doxazosin Mesylate | 143 | $1,627 |
| Cinacalcet Hcl | 28 | $1,281 |
| Potassium Chloride | 73 | $974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aurinia Pharma U.S., Inc.Lupkynis | $506 | $107,02411 claims |
| AstraZenecaFarxiga, Lokelma | $791 | $55,81589 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $564 | $29,64621 claims |
| Lilly USA, LLCTrulicity | $51 | $24,15424 claims |
| Novo NordiskOzempic | $373 | $20,09623 claims |
| Boehringer IngelheimJardiance | $128 | $10,28719 claims |
| NovartisEntresto | $344 | $9,12513 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $68 | $71732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,184 adult health providers in Ohio.
Other adult health in Cortland
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Teresa ShafferBoardman$102K
- Jesse McClainYoungstown$79K
- Lucretia LongColumbus$76K
- Marybeth RivardColumbus$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.